Aryl Hydrocarbon Receptor in Health and Disease

Abstract

The aryl hydrocarbon receptor (AhR) functions as a ligand-dependent transcription factor, serving as a pivotal environmental sensor that significantly influences both physiological and pathological processes. The inactivated state of AhR is present in the cell cytoplasm and transfer into the nucleus upon activation by a variety of ligands. It subsequently regulates a variety of processes including cellular metabolism, organ and tissue development, and maintenance of immune homeostasis. Despite substantial advancements over the past decade, the mechanisms by which AhR specifically regulates immune cell function in response to environmental factors and influences disease progression remain not fully elucidated. This review systematically analyzes the basic structure and major signaling pathways of AhR, its physiological functions in maintaining organismal homeostasis and its mechanism of action on various types of immune cells, and their therapeutic potential in autoimmune diseases, inflammatory disorders, tumor microenvironment, and neurodegenerative diseases. Translating immune-metabolic reprogramming mechanisms into clinical applications represents a pivotal challenge in AhR research. And this review integrates and analyzes the great potential of AhR as a pleiotropic therapeutic target for regulating immunity and treating a series of diseases, offering actionable frameworks for future exploration.

Keywords

AhR / immune cells / signaling pathways / treatment strategies

References

[1] D. Riddick, “Fifty Years of Aryl Hydrocarbon Receptor Research as Reflected in the Pages of Drug Metabolism and Disposition,” Drug Metabolism and Disposition 51, no. 6 (2023): 657-671.

[2] W. Huang, K. Rui, X. Wang, et al., “The Aryl Hydrocarbon Receptor in Immune Regulation and Autoimmune Pathogenesis,” Journal of Autoimmunity 138 (2023): 103049.

[3] C. A. Opitz, P. Holfelder, M. T. Prentzell, and S. Trump, “The Complex Biology of Aryl Hydrocarbon Receptor Activation in Cancer and Beyond,” Biochemical Pharmacology 216 (2023): 115798.

[4] K. Bock, “Aryl Hydrocarbon Receptor (AHR) Functions: Balancing Opposing Processes Including Inflammatory Reactions,” Biochemical Pharmacology 178 (2020): 114093.

[5] J. Cheong and L. Sun, “Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy—Challenges and Opportunities,” Trends in Pharmacological Sciences 39, no. 3 (2018): 307-325.

[6] S. Lamorte, R. Shinde, and T. McGaha, “Nuclear Receptors, the Aryl Hydrocarbon Receptor, and Macrophage Function,” Molecular Aspects of Medicine 78 (2021): 100942.

[7] B. Stockinger, P. D. Meglio, M. Gialitakis, and J. H. Duarte, “The Aryl Hydrocarbon Receptor: Multitasking in the Immune System,” Annual Review of Immunology 32 (2014): 403-432.

[8] K. W. Schulte, E. Green, A. Wilz, M. Platten, and O. Daumke, “Structural Basis for Aryl Hydrocarbon Receptor-Mediated Gene Activation,” Structure (London, England) 25, no. 7 (2017): 1025-1033. e3.

[9] L. Bonati, S. Motta, and L. Callea, “The AhR Signaling Mechanism: A Structural Point of View,” Journal of Molecular Biology 436, no. 3 (2024): 168296.

[10] Z. Wen, Y. Zhang, B. Zhang, et al., “Cryo-EM Structure of the Cytosolic AhR Complex,” Structure (London, England) 31, no. 3 (2023): 295-308. e4.

[11] N. Hao and M. Whitelaw, “The Emerging Roles of AhR in Physiology and Immunity,” Biochemical Pharmacology 86, no. 5 (2013): 561-570.

[12] X. Wang, F. Cao, Y. Zhang, and H. Pan, “Therapeutic Potential of Aryl Hydrocarbon Receptor in Autoimmunity,” Inflammopharmacology 28, no. 1 (2020): 63-81.

[13] P. M. Nguyen, D. Wang, Y. Wang, Y. Li, J. A. Uchizono, and W. K. Chan, “p23 co-chaperone Protects the Aryl Hydrocarbon Receptor From Degradation in Mouse and human Cell Lines,” Biochemical Pharmacology 84, no. 6 (2012): 838-850.

[14] S. Dai, L. Qu, J. Li, et al., “Structural Insight Into the Ligand Binding Mechanism of Aryl Hydrocarbon Receptor,” Nature Communications 13, no. 1 (2022): 6234.

[15] A. Tkachenko, M. Bermudez, S. Irmer-Stooff, et al., “Nuclear Transport of the human Aryl Hydrocarbon Receptor and Subsequent Gene Induction Relies on Its Residue Histidine 291,” Archives of Toxicology 92, no. 3 (2018): 1151-1160.

[16] V. Rothhammer and F. Quintana, “The Aryl Hydrocarbon Receptor: An Environmental Sensor Integrating Immune Responses in Health and Disease,” Nature Reviews Immunology 19, no. 3 (2019): 184-197.

[17] D. R. Neavin, D. Liu, B. Ray, and R. M. Weinshilboum, “The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases,” International Journal of Molecular Sciences 19, no. 12 (2018): 3851.

[18] R. Shinde and T. McGaha, “The Aryl Hydrocarbon Receptor: Connecting Immunity to the Microenvironment,” Trends in Immunology 39, no. 12 (2018): 1005-1020.

[19] L. Larigot, L. Benoit, M. Koual, C. Tomkiewicz, R. Barouki, and X. Coumoul, “Aryl Hydrocarbon Receptor and Its Diverse Ligands and Functions: An Exposome Receptor,” Annual Review of Pharmacology and Toxicology 62 (2022): 383-404.

[20] N. Prasad Singh, M. Nagarkatti, and P. Nagarkatti, “From Suppressor T Cells to Regulatory T Cells: How the Journey That Began With the Discovery of the Toxic Effects of TCDD Led to Better Understanding of the Role of AhR in Immunoregulation,” International Journal of Molecular Sciences 21, no. 21 (2020): 7849.

[21] A. Schecter, L. Birnbaum, J. J. Ryan, and J. D. Constable, “Dioxins: An Overview,” Environmental Research 101, no. 3 (2006): 419-428.

[22] T. Stone and R. Williams, “Modulation of T Cells by Tryptophan Metabolites in the Kynurenine Pathway,” Trends in Pharmacological Sciences 44, no. 7 (2023): 442-456.

[23] A. Rannug and U. Rannug, “The Tryptophan Derivative 6-formylindolo[3,2-b]Carbazole, FICZ, a Dynamic Mediator of Endogenous Aryl Hydrocarbon Receptor Signaling, Balances Cell Growth and Differentiation,” Critical Reviews in Toxicology 48, no. 7 (2018): 555-574.

[24] D. Dolciami, M. Gargaro, B. Cerra, et al., “Binding Mode and Structure-Activity Relationships of ITE as an Aryl Hydrocarbon Receptor (AhR) Agonist,” Chemmedchem 13, no. 3 (2018): 270-279.

[25] J. Liu, H. Miao, D. Deng, N. D. Vaziri, P. Li, and Y. Zhao, “Gut Microbiota-derived Tryptophan Metabolism Mediates Renal Fibrosis by Aryl Hydrocarbon Receptor Signaling Activation,” Cellular and Molecular Life Sciences 78, no. 3 (2021): 909-922.

[26] L. Pernomian, M. Duarte-Silva, and C. de Barros Cardoso, “The Aryl Hydrocarbon Receptor (AHR) as a Potential Target for the Control of Intestinal Inflammation: Insights From an Immune and Bacteria Sensor Receptor,” Clinical Reviews in Allergy & Immunology 59, no. 3 (2020): 382-390.

[27] F. Bahman, K. Choudhry, F. Al-Rashed, F. Al-Mulla, S. Sindhu, and R. Ahmad, “Aryl Hydrocarbon Receptor: Current Perspectives on Key Signaling Partners and Immunoregulatory Role in Inflammatory Diseases,” Frontiers in Immunology 15 (2024): 1421346.

[28] P. Wee and Z. Wang, “Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways,” Cancers (Basel) 9, no. 5 (2017): 52.

[29] K. Wang, J. Zheng, J. Yu, et al., “Knockdown of MMP‑1 Inhibits the Progression of Colorectal Cancer by Suppressing the PI3K/Akt/c‑Myc Signaling Pathway and EMT,” Oncology Reports 43, no. 4 (2020): 1103-1112.

[30] H. Feng, B. Cao, X. Peng, and Q. Wei, “Cancer-associated Fibroblasts Strengthen Cell Proliferation and EGFR TKIs Resistance Through Aryl Hydrocarbon Receptor Dependent Signals in Non-small Cell Lung Cancer,” BMC Cancer 22, no. 1 (2022): 764.

[31] Y. Wei, X. Liu, Y. Jiang, et al., “Maintenance of Airway Epithelial Barrier Integrity via the Inhibition of AHR/EGFR Activation Ameliorates Chronic Obstructive Pulmonary Disease Using Effective-component Combination,” Phytomedicine 118 (2023): 154980.

[32] H. Takanaga, T. Yoshitake, E. Yatabe, S. Hara, and M. Kunimoto, “Beta-naphthoflavone Disturbs Astrocytic Differentiation of C6 Glioma Cells by Inhibiting Autocrine Interleukin-6,” Journal of Neurochemistry 90, no. 3 (2004): 750-757.

[33] T. Takizawa, M. Yanagisawa, W. Ochiai, et al., “Directly Linked Soluble IL-6 Receptor-IL-6 Fusion Protein Induces Astrocyte Differentiation From Neuroepithelial Cells via Activation of STAT3,” Cytokine 13, no. 5 (2001): 272-279.

[34] Y. Liu, N. Zhou, L. Zhou, et al., “IL-2 Regulates Tumor-reactive CD8(+) T Cell Exhaustion by Activating the Aryl Hydrocarbon Receptor,” Nature Immunology 22, no. 3 (2021): 358-369.

[35] M. Platten, E. A. A. Nollen, U. F. Röhrig, F. Fallarino, and C. A. Opitz, “Tryptophan Metabolism as a Common Therapeutic Target in Cancer, Neurodegeneration and Beyond,” Nature Reviews Drug Discovery 18, no. 5 (2019): 379-401.

[36] S. Luecke-Johansson, M. Gralla, H. Rundqvist, et al., “A Molecular Mechanism To Switch the Aryl Hydrocarbon Receptor From a Transcription Factor to an E3 Ubiquitin Ligase,” Molecular and Cellular Biology 37, no. 13 (2017): e00630-16.

[37] H. Yu, L. Lin, Z. Zhang, H. Zhang, and H. Hu, “Targeting NF-κB Pathway for the Therapy of Diseases: Mechanism and Clinical Study,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 209.

[38] Y. Tian, S. Ke, M. Denison, A. B. Rabson, and M. A. Gallo, “Ah Receptor and NF-kappaB Interactions, a Potential Mechanism for Dioxin Toxicity,” Journal of Biological Chemistry 274, no. 1 (1999): 510-515.

[39] B. C. DiNatale, J. C. Schroeder, L. J. Francey, A. Kusnadi, and G. H. Perdew, “Mechanistic Insights Into the Events That Lead to Synergistic Induction of Interleukin 6 Transcription Upon Activation of the Aryl Hydrocarbon Receptor and Inflammatory Signaling,” Journal of Biological Chemistry 285, no. 32 (2010): 24388-24397.

[40] R. D. Patel, I. A. Murray, C. A. Flaveny, A. Kusnadi, and G. H. Perdew, “Ah Receptor Represses Acute-phase Response Gene Expression Without Binding to Its Cognate Response Element,” Laboratory Investigation 89, no. 6 (2009): 695-707.

[41] P. Zhu, H. Yu, K. Zhou, Y. Bai, R. Qi, and S. Zhang, “3,3'-Diindolylmethane Modulates Aryl Hydrocarbon Receptor of Esophageal Squamous Cell Carcinoma to Reverse Epithelial-mesenchymal Transition Through Repressing RhoA/ROCK1-mediated COX2/PGE(2) Pathway,” Journal of Experimental & Clinical Cancer Research 39, no. 1 (2020): 113.

[42] P. Ghezzi, B. Saccardo, and M. Bianchi, “Recombinant Tumor Necrosis Factor Depresses Cytochrome P450-dependent Microsomal Drug Metabolism in Mice,” Biochemical and Biophysical Research Communications 136, no. 1 (1986): 316-321.

[43] C. Barker, J. Fagan, and D. Pasco, “Interleukin-1 Beta Suppresses the Induction of P4501A1 and P4501A2 mRNAs in Isolated Hepatocytes,” Journal of Biological Chemistry 267, no. 12 (1992): 8050-8055.

[44] L. Slemc and T. Kunej, “Transcription Factor HIF1A: Downstream Targets, Associated Pathways, Polymorphic Hypoxia Response Element (HRE) Sites, and Initiative for Standardization of Reporting in Scientific Literature,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 37, no. 11 (2016): 14851-14861.

[45] S. Sakurai, T. Shimizu, and U. Ohto, “The Crystal Structure of the AhRR-ARNT Heterodimer Reveals the Structural Basis of the Repression of AhR-mediated Transcription,” Journal of Biological Chemistry 292, no. 43 (2017): 17609-17616.

[46] M. Zhang, Y. Hu, F. Yang, et al., “Interaction Between AhR and HIF-1 Signaling Pathways Mediated by ARNT/HIF-1β,” BMC Pharmacology and Toxicology 23, no. 1 (2022): 26.

[47] R. Pollenz, N. Davarinos, and T. Shearer, “Analysis of Aryl Hydrocarbon Receptor-mediated Signaling During Physiological Hypoxia Reveals Lack of Competition for the Aryl Hydrocarbon Nuclear Translocator Transcription Factor,” Molecular Pharmacology 56, no. 6 (1999): 1127-1137.

[48] K. Haas, H. Weighardt, R. Deenen, et al., “Aryl Hydrocarbon Receptor in Keratinocytes Is Essential for Murine Skin Barrier Integrity,” Journal of Investigative Dermatology 136, no. 11 (2016): 2260-2269.

[49] G. Gabriely, M. A. Wheeler, M. C. Takenaka, and F. J. Quintana, “Role of AHR and HIF-1α in Glioblastoma Metabolism,” Trends in Endocrinology and Metabolism 28, no. 6 (2017): 428-436.

[50] P. Tarnow, T. Tralau, and A. Luch, “Chemical Activation of Estrogen and Aryl Hydrocarbon Receptor Signaling Pathways and Their Interaction in Toxicology and Metabolism,” Expert Opinion on Drug Metabolism & Toxicology 15, no. 3 (2019): 219-229.

[51] Y. Tsuchiya, M. Nakajima, and T. Yokoi, “Cytochrome P450-mediated Metabolism of Estrogens and Its Regulation in human,” Cancer Letters 227, no. 2 (2005): 115-124.

[52] S. Safe, F. Wang, W. Porter, R. Duan, and A. McDougal, “Ah Receptor Agonists as Endocrine Disruptors: Antiestrogenic Activity and Mechanisms,” Toxicology Letters 102-103 (1998): 343-347.

[53] F. Ohtake, Y. Fujii-Kuriyama, and S. Kato, “AhR Acts as an E3 Ubiquitin Ligase to Modulate Steroid Receptor Functions,” Biochemical Pharmacology 77, no. 4 (2009): 474-484.

[54] T. Gasiewicz, K. Singh, and J. Bennett, “The Ah Receptor in Stem Cell Cycling, Regulation, and Quiescence,” Annals of the New York Academy of Sciences 1310 (2014): 44-50.

[55] S. Mulero-Navarro and P. Fernandez-Salguero, “New Trends in Aryl Hydrocarbon Receptor Biology,” Frontiers in Cell and Developmental Biology 4 (2016): 45.

[56] A. Bosi, D. Banfi, M. Bistoletti, C. Giaroni, and A. Baj, “Tryptophan Metabolites along the Microbiota-Gut-Brain Axis: An Interkingdom Communication System Influencing the Gut in Health and Disease,” International Journal of Tryptophan Research 13 (2020): 1178646920928984.

[57] H. Roager and T. Licht, “Microbial Tryptophan Catabolites in Health and Disease,” Nature Communications 9, no. 1 (2018): 3294.

[58] F. J. Quintana, A. S. Basso, A. H. Iglesias, et al., “Control of T(reg) and T(H)17 Cell Differentiation by the Aryl Hydrocarbon Receptor,” Nature 453, no. 7191 (2008): 65-71.

[59] B. Vaidyanathan, A. Chaudhry, W. T. Yewdell, et al., “The Aryl Hydrocarbon Receptor Controls Cell-fate Decisions in B Cells,” Journal of Experimental Medicine 214, no. 1 (2017): 197-208.

[60] D. Sherr and S. Monti, “The Role of the Aryl Hydrocarbon Receptor in Normal and Malignant B Cell Development,” Seminars in Immunopathology 35, no. 6 (2013): 705-716.

[61] M. Villa, M. Gialitakis, M. Tolaini, et al., “Aryl Hydrocarbon Receptor Is Required for Optimal B-cell Proliferation,” Embo Journal 36, no. 1 (2017): 116-128.

[62] P. D'Addabbo, D. Frezza, and C. Sulentic, “Evolutive Emergence and Divergence of an Ig Regulatory Node: An Environmental Sensor Getting Cues From the Aryl Hydrocarbon Receptor?,” Frontiers in Immunology 14 (2023): 996119.

[63] M. S. Bhakta-Yadav, K. Burra, N. Alhamdan, C. P. Allex-Buckner, and C. E. W. Sulentic, “The Aryl Hydrocarbon Receptor Differentially Modulates the Expression Profile of Antibody Isotypes in a human B-cell Line,” Toxicological Sciences 199, no. 2 (2024): 276-288.

[64] L. K. Blevins, J. Zhou, R. B. Crawford, and N. E. Kaminski, “Identification of a Sensitive Human Immunological Target of Aryl Hydrocarbon Receptor Activation: CD5(+) Innate-Like B Cells,” Frontiers in Immunology 12 (2021): 635748.

[65] L. Hiéronimus and F. Huaux, “B-1 Cells in Immunotoxicology: Mechanisms Underlying Their Response to Chemicals and Particles,” Frontiers in Toxicology 5 (2023): 960861.

[66] T. Yoshida, K. Katsuya, T. Oka, et al., “Effects of AhR Ligands on the Production of Immunoglobulins in Purified Mouse B Cells,” Biomedical Research 33, no. 2 (2012): 67-74.

[67] F. Ohtake, K. Takeyama, T. Matsumoto, et al., “Modulation of Oestrogen Receptor Signalling by Association With the Activated Dioxin Receptor,” Nature 423, no. 6939 (2003): 545-550.

[68] C. J. Piper, E. C. Rosser, K. Oleinika, et al., “Aryl Hydrocarbon Receptor Contributes to the Transcriptional Program of IL-10-Producing Regulatory B Cells,” Cell Reports 29, no. 7 (2019): 1878-1892. e7.

[69] M. Veldhoen, K. Hirota, J. Christensen, A. O'Garra, and B. Stockinger, “Natural Agonists for Aryl Hydrocarbon Receptor in Culture Medium Are Essential for Optimal Differentiation of Th17 T Cells,” Journal of Experimental Medicine 206, no. 1 (2009): 43-49.

[70] X. Liu, H. Hu, H. Fan, et al., “The Role of STAT3 and AhR in the Differentiation of CD4+ T Cells Into Th17 and Treg Cells,” Medicine 96, no. 17 (2017): e6615.

[71] F. Ohtake, A. Baba, I. Takada, et al., “Dioxin Receptor Is a Ligand-dependent E3 Ubiquitin Ligase,” Nature 446, no. 7135 (2007): 562-566.

[72] C. Dong, “TH17 cells in Development: An Updated View of Their Molecular Identity and Genetic Programming,” Nature Reviews Immunology 8, no. 5 (2008): 337-348.

[73] E. Baricza, V. Tamási, N. Marton, E. I. Buzás, and G. Nagy, “The Emerging Role of Aryl Hydrocarbon Receptor in the Activation and Differentiation of Th17 Cells,” Cellular and Molecular Life Sciences 73, no. 1 (2016): 95-117.

[74] S. Sakaguchi, K. Wing, and M. Miyara, “Regulatory T Cells—a Brief History and Perspective,” European Journal of Immunology 37, no. Suppl 1 (2007): S116-S123.

[75] X. Yuan, B. Tong, Y. Dou, X. Wu, Z. Wei, and Y. Dai, “Tetrandrine Ameliorates Collagen-induced Arthritis in Mice by Restoring the Balance Between Th17 and Treg Cells via the Aryl Hydrocarbon Receptor,” Biochemical Pharmacology 101 (2016): 87-99.

[76] R. Gandhi, D. Kumar, E. J. Burns, et al., “Activation of the Aryl Hydrocarbon Receptor Induces human Type 1 Regulatory T Cell-Like and Foxp3(+) Regulatory T Cells,” Nature Immunology 11, no. 9 (2010): 846-853.

[77] N. P. Singh, U. P. Singh, B. Singh, R. L. Price, M. Nagarkatti, and P. S. Nagarkatti, “Activation of Aryl Hydrocarbon Receptor (AhR) Leads to Reciprocal Epigenetic Regulation of FoxP3 and IL-17 Expression and Amelioration of Experimental Colitis,” PLoS ONE 6, no. 8 (2011): e23522.

[78] N. T. Nguyen, A. Kimura, T. Nakahama, et al., “Aryl Hydrocarbon Receptor Negatively Regulates Dendritic Cell Immunogenicity via a Kynurenine-dependent Mechanism,” PNAS 107, no. 46 (2010): 19961-19966.

[79] Z. Liu, L. Sun, Y. Cai, et al., “Hypoxia-Induced Suppression of Alternative Splicing of MBD2 Promotes Breast Cancer Metastasis via Activation of FZD1,” Cancer Research 81, no. 5 (2021): 1265-1278.

[80] T. Negishi, Y. Kato, O. Ooneda, et al., “Effects of Aryl Hydrocarbon Receptor Signaling on the Modulation of TH1/TH2 Balance,” Journal of Immunology 175, no. 11 (2005): 7348-7356.

[81] T. Simones and D. Shepherd, “Consequences of AhR Activation in Steady-state Dendritic Cells,” Toxicological Sciences 119, no. 2 (2011): 293-307.

[82] K. R. Wilson, D. Jenika, A. B. Blum, et al., “MHC Class II Ubiquitination Regulates Dendritic Cell Function and Immunity,” Journal of Immunology 207, no. 9 (2021): 2255-2264.

[83] V. E. Woodhead, T. J. Stonehouse, M. H. Binks, et al., “Novel Molecular Mechanisms of Dendritic Cell-induced T Cell Activation,” International Immunology 12, no. 7 (2000): 1051-1061.

[84] Y. Tai, Q. Wang, H. Korner, L. Zhang, and W. Wei, “Molecular Mechanisms of T Cells Activation by Dendritic Cells in Autoimmune Diseases,” Frontiers in Pharmacology 9 (2018): 642.

[85] Q. Li, J. L. Harden, C. D. Anderson, and N. K. Egilmez, “Tolerogenic Phenotype of IFN-γ-Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO-Kynurenine/AhR-IDO Loop,” Journal of Immunology 197, no. 3 (2016): 962-970.

[86] C. Vlachos, B. Schulte, P. Magiatis, G. Adema, and G. Gaitanis, “Malassezia-derived Indoles Activate the Aryl Hydrocarbon Receptor and Inhibit Toll-Like Receptor-induced Maturation in Monocyte-derived Dendritic Cells,” British Journal of Dermatology 167, no. 3 (2012): 496-505.

[87] D. Gabrilovich and S. Nagaraj, “Myeloid-derived Suppressor Cells as Regulators of the Immune System,” Nature Reviews Immunology 9, no. 3 (2009): 162-174.

[88] K. R. Crook, “Role of Myeloid-derived Suppressor Cells in Autoimmune Disease,” World Journal of Immunology 4, no. 1 (2014): 26-33.

[89] W. H. Neamah, P. B. Busbee, H. Alghetaa, O. A. Abdulla, M. Nagarkatti, and P. Nagarkatti, “AhR Activation Leads to Alterations in the Gut Microbiome With Consequent Effect on Induction of Myeloid Derived Suppressor Cells in a CXCR2-Dependent Manner,” International Journal of Molecular Sciences 21, no. 24 (2020): 9613.

[90] S. Jian, W. Chen, Y. Su, et al., “Glycolysis Regulates the Expansion of Myeloid-derived Suppressor Cells in Tumor-bearing Hosts Through Prevention of ROS-mediated Apoptosis,” Cell Death & Disease 8, no. 5 (2017): e2779.

[91] W. H. Neamah, N. P. Singh, H. Alghetaa, et al., “AhR Activation Leads to Massive Mobilization of Myeloid-Derived Suppressor Cells With Immunosuppressive Activity Through Regulation of CXCR2 and MicroRNA miR-150-5p and miR-543-3p That Target Anti-Inflammatory Genes,” Journal of Immunology 203, no. 7 (2019): 1830-1844.

[92] B. Hoechst, J. Gamrekelashvili, M. P. Manns, T. F. Greten, and F. Korangy, “Plasticity of human Th17 Cells and iTregs Is Orchestrated by Different Subsets of Myeloid Cells,” Blood 117, no. 24 (2011): 6532-6541.

[93] D. Mosser and J. Edwards, “Exploring the Full Spectrum of Macrophage Activation,” Nature Reviews Immunology 8, no. 12 (2008): 958-969.

[94] S. Climaco-Arvizu, O. Domínguez-Acosta, M. A. Cabañas-Cortés, et al., “Aryl Hydrocarbon Receptor Influences Nitric Oxide and Arginine Production and Alters M1/M2 Macrophage Polarization,” Life Sciences 155 (2016): 76-84.

[95] A. Alzahrani and H. Hanieh, “Differential Modulation of Ahr and Arid5a: A Promising Therapeutic Strategy for Autoimmune Encephalomyelitis,” Saudi Pharmaceutical Journal 28, no. 12 (2020): 1605-1615.

[96] Y. Huang, J. He, H. Liang, et al., “Aryl Hydrocarbon Receptor Regulates Apoptosis and Inflammation in a Murine Model of Experimental Autoimmune Uveitis,” Frontiers in Immunology 9 (2018): 1713.

[97] W. Dai, S. Yin, F. Wang, et al., “Punicalagin as a Novel Selective Aryl Hydrocarbon Receptor (AhR) Modulator Upregulates AhR Expression Through the PDK1/p90RSK/AP-1 Pathway to Promote the Anti-inflammatory Response and Bactericidal Activity of Macrophages,” Cell Communication and Signaling 22, no. 1 (2024): 473.

[98] S. D. Scoville, A. P. Nalin, L. Chen, et al., “Human AML Activates the Aryl Hydrocarbon Receptor Pathway to Impair NK Cell Development and Function,” Blood 132, no. 17 (2018): 1792-1804.

[99] Z. Shi, H. Ohno, and N. Satoh-Takayama, “Dietary Derived Micronutrients Modulate Immune Responses through Innate Lymphoid Cells,” Frontiers in Immunology 12 (2021): 670632.

[100] E. Helm and L. Zhou, “Transcriptional Regulation of Innate Lymphoid Cells and T Cells by Aryl Hydrocarbon Receptor,” Frontiers in Immunology 14 (2023): 1056267.

[101] Q. Ye, S. Huang, Y. Wang, et al., “Wogonin Improves Colitis by Activating the AhR Pathway to Regulate the Plasticity of ILC3/ILC1,” Phytomedicine 128 (2024): 155425.

[102] J. Wu, K. Wang, X. Qi, et al., “The Intestinal Fungus Aspergillus tubingensis Promotes Polycystic Ovary Syndrome Through a Secondary Metabolite,” Cell Host & Microbe 33, no. 1 (2025): 119-136. e11.

[103] S. Li, J. Zhu, J. Song, et al., “Aryl Hydrocarbon Receptor, a Promising Therapeutic Target for Ulcerative Colitis, Impairs HK2-controlled Flux of Hexosamine-biosynthesis Pathway to Eliminate NETosis in an N-glycosylation Dependent Manner,” Journal of Advanced Research (2025).

[104] Y. Hu, H. Li, X. Wang, et al., “Activation of the Aryl Hydrocarbon Receptor Alleviates Sjögren's Syndrome by Promoting Bregs Differentiation,” International Immunopharmacology 158 (2025): 114812.

[105] Y. Wei, N. Peng, C. Deng, et al., “Aryl Hydrocarbon Receptor Activation Drives Polymorphonuclear Myeloid-derived Suppressor Cell Response and Efficiently Attenuates Experimental Sjögren's Syndrome,” Cellular & Molecular Immunology 19, no. 12 (2022): 1361-1372.

[106] A. Abdullah, M. Maged, I. Hairul-Islam M, et al., “Activation of Aryl Hydrocarbon Receptor Signaling by a Novel Agonist Ameliorates Autoimmune Encephalomyelitis,” PLoS ONE 14, no. 4 (2019): e0215981.

[107] Q. Lv, C. Shi, S. Qiao, et al., “Alpinetin Exerts Anti-colitis Efficacy by Activating AhR, Regulating miR-302/DNMT-1/CREB Signals, and Therefore Promoting Treg Differentiation,” Cell Death & Disease 9, no. 9 (2018): 890.

[108] L. Xie, S. Cai, H. Lu, et al., “Microbiota-derived I3A Protects the Intestine Against Radiation Injury by Activating AhR/IL-10/Wnt Signaling and Enhancing the Abundance of Probiotics,” Gut Microbes 16, no. 1 (2024): 2347722.

[109] Z. Huang, Y. Jiang, Y. Yang, et al., “3,3'-Diindolylmethane Alleviates Oxazolone-induced Colitis Through Th2/Th17 Suppression and Treg Induction,” Molecular Immunology 53, no. 4 (2013): 335-344.

[110] S. Liu, W. Yan, Q. Lv, et al., “3, 3'-diindolylmethane, a Natural Aryl Hydrocarbon Receptor Agonist, Alleviates Ulcerative Colitis by Enhancing "Glycolysis-lactate-STAT3″ and TIP60 Signals-mediated Treg Differentiation,” Molecular Immunology 163 (2023): 147-162.

[111] S. Li, J. Zhu, J. Song, et al., “Aryl Hydrocarbon Receptor Impairs HK2-controlled Flux of the Hexosamine Biosynthesis Pathway to Suppress NETosis in an N-glycosylation-dependent Manner,” Journal of Advanced Research (2025).

[112] Y. Zhang, Y. Pan, P. Zhang, et al., “AhR Agonist tapinarof Ameliorates Lupus Autoimmunity by Suppressing Tfh Cell Differentiation via Regulation of the JAK2-STAT3 Signaling Pathway,” Immunity, Inflammation and Disease 11, no. 6 (2023): e903.

[113] X. Su, X. Wang, X. Zhang, Y. Sun, and Y. Jia, “β-Indole-3-acetic Acid Attenuated Collagen-induced Arthritis Through Reducing the Ubiquitination of Foxp3 via the AhR-TAZ-Tip60 Pathway,” Immunologic Research 72, no. 4 (2024): 741-753.

[114] E. C. Rosser, C. J. Piper, D. E. Matei, et al., “Microbiota-Derived Metabolites Suppress Arthritis by Amplifying Aryl-Hydrocarbon Receptor Activation in Regulatory B Cells,” Cell Metabolism 31, no. 4 (2020): 837-851. e10.

[115] S. Chen, H. Hu, J. Wu, et al., “Activation of Aryl Hydrocarbon Receptor Ameliorates Degranulation of LL-37 Induced Mast Cells in rosacea Through Enhancing Autophagy,” International Immunopharmacology 146 (2025): 113910.

[116] N. Jonić, I. Koprivica, S. G. Kyrkou, et al., “Novel AHR Ligand AGT-5 Ameliorates Type 1 Diabetes in Mice Through Regulatory Cell Activation in the Early Phase of the Disease,” Frontiers in Immunology 15 (2024): 1454156.

[117] S. Ma, X. Li, T. Duan, et al., “Moshen Granule Ameliorates Membranous Nephropathy by Regulating NF-ƙB/Nrf2 Pathways via Aryl Hydrocarbon Receptor Signalling,” Heliyon 9, no. 9 (2023): e20019.

[118] E. van den Bogaard, J. G. Bergboer, M. Vonk-Bergers, et al., “Coal Tar Induces AHR-dependent Skin Barrier Repair in Atopic Dermatitis,” Journal of Clinical Investigation 123, no. 2 (2013): 917-927.

[119] Y. Guéguen, K. Mouzat, L. Ferrari, et al., “[Cytochromes P450: Xenobiotic metabolism, regulation and clinical importance],” Annales de Biologie Clinique (Paris) 64, no. 6 (2006): 535-548.

[120] J. Hukkanen, “Induction of Cytochrome P450 Enzymes: A View on human in Vivo Findings,” Expert Review of Clinical Pharmacology 5, no. 5 (2012): 569-585.

[121] N. Kanojia, S. Kukal, N. Machahary, et al., “Antiepileptic Drugs Carbamazepine and Valproic Acid Mediate Transcriptional Activation of CYP1A1 via Aryl Hydrocarbon Receptor and Regulation of Estrogen Metabolism,” Journal of Steroid Biochemistry and Molecular Biology 248 (2025): 106699.

[122] K. Bock, “Aryl Hydrocarbon Receptor (AHR), Integrating Energy Metabolism and Microbial or Obesity-mediated Inflammation,” Biochemical Pharmacology 184 (2021): 114346.

[123] Y. Gao, K. Liu, W. Xiao, et al., “Aryl Hydrocarbon Receptor Confers Protection Against Macrophage Pyroptosis and Intestinal Inflammation Through Regulating Polyamine Biosynthesis,” Theranostics 14, no. 11 (2024): 4218-4239.

[124] A. Sahebnasagh, J. Hashemi, A. Khoshi, et al., “Aromatic Hydrocarbon Receptors in Mitochondrial Biogenesis and Function,” Mitochondrion 61 (2021): 85-101.

[125] M. J. Heo, J. H. Suh, S. H. Lee, et al., “Aryl Hydrocarbon Receptor Maintains Hepatic Mitochondrial Homeostasis in Mice,” Molecular Metabolism 72 (2023): 101717.

[126] A. Gao, J. Jiang, F. Xie, and L. Chen, “Bnip3 in Mitophagy: Novel Insights and Potential Therapeutic Target for Diseases of Secondary Mitochondrial Dysfunction,” Clinica Chimica Acta 506 (2020): 72-83.

[127] N. Balestrieri, V. Palzkill, C. Pass, et al., “Activation of the Aryl Hydrocarbon Receptor in Muscle Exacerbates Ischemic Pathology in Chronic Kidney Disease,” Circulation Research 133, no. 2 (2023): 158-176.

[128] L. F. Fitzgerald, J. Lackey, A. Moussa, et al., “Chronic Aryl Hydrocarbon Receptor Activity Impairs Muscle Mitochondrial Function With Tobacco Smoking,” Journal of Cachexia, Sarcopenia and Muscle 15, no. 2 (2024): 646-659.

[129] T. Thome, N. A. Vugman, L. E. Stone, K. Wimberly, S. T. Scali, and T. E. Ryan, “A Tryptophan-derived Uremic Metabolite/Ahr/Pdk4 Axis Governs Skeletal Muscle Mitochondrial Energetics in Chronic Kidney Disease,” JCI Insight 9, no. 10 (2024): e178372.

[130] B. Wang and A. Xu, “Aryl Hydrocarbon Receptor Pathway Participates in Myocardial Ischemia Reperfusion Injury by Regulating Mitochondrial Apoptosis,” Medical Hypotheses 123 (2019): 2-5.

[131] M. Zhang, J. Chen, Y. Jiang, and T. Chen, “Fine Particulate Matter Induces Heart Defects via AHR/ROS-mediated Endoplasmic Reticulum Stress,” Chemosphere 307, no. Pt 2 (2022): 135962.

[132] H. Xie, N. Yang, L. Lu, et al., “Uremic Toxin Receptor AhR Facilitates Renal Senescence and Fibrosis via Suppressing Mitochondrial Biogenesis,” Advanced Science (Weinheim) 11, no. 33 (2024): e2402066.

[133] E. B. Harstad, C. A. Guite, T. L. Thomae, and C. A. Bradfield, “Liver Deformation in Ahr-null Mice: Evidence for Aberrant Hepatic Perfusion in Early Development,” Molecular Pharmacology 69, no. 5 (2006): 1534-1541.

[134] M. K. Bunger, E. Glover, S. M. Moran, et al., “Abnormal Liver Development and Resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin Toxicity in Mice Carrying a Mutation in the DNA-binding Domain of the Aryl Hydrocarbon Receptor,” Toxicological Sciences 106, no. 1 (2008): 83-92.

[135] Y. Li, K. Wang, Q. Zou, R. R. Magness, and J. Zheng, “2,3,7,8-Tetrachlorodibenzo-p-dioxin Differentially Suppresses Angiogenic Responses in human Placental Vein and Artery Endothelial Cells,” Toxicology 336 (2015): 70-78.

[136] M. Volkova, M. Palmeri, K. S. Russell, and R. R. Russell, “Activation of the Aryl Hydrocarbon Receptor by Doxorubicin Mediates Cytoprotective Effects in the Heart,” Cardiovascular Research 90, no. 2 (2011): 305-314.

[137] X. Lin, W. Liu, Y. Chu, et al., “Activation of AHR by ITE Improves Cardiac Remodelling and Function in Rats After Myocardial Infarction,” ESC Heart Failure 10, no. 6 (2023): 3622-3636.

[138] E. Seong, J. Lee, S. Lim, et al., “Activation of Aryl Hydrocarbon Receptor by ITE Improves Cardiac Function in Mice after Myocardial Infarction,” Journal of the American Heart Association 10, no. 13 (2021): e020502.

[139] B. Shi, X. Zhang, Z. Song, et al., “Targeting Gut Microbiota-derived Kynurenine to Predict and Protect the Remodeling of the Pressure-overloaded Young Heart,” Science Advances 9, no. 28 (2023): eadg7417.

[140] M. Tamayo, L. Martín-Nunes, M. J. Piedras, et al., “The Aryl Hydrocarbon Receptor Ligand FICZ Improves Left Ventricular Remodeling and Cardiac Function at the Onset of Pressure Overload-Induced Heart Failure in Mice,” International Journal of Molecular Sciences 23, no. 10 (2022): 5403.

[141] J. M. Bradley, K. A. Cryar, M. C. El Hajj, E. C. El Hajj, and J. D. Gardner, “Exposure to Diesel Exhaust Particulates Induces Cardiac Dysfunction and Remodeling,” Journal of Applied Physiology (1985) 115, no. 7 (2013): 1099-1106.

[142] L. Juricek and X. Coumoul, “The Aryl Hydrocarbon Receptor and the Nervous System,” International Journal of Molecular Sciences 19, no. 9 (2018): 2504.

[143] D. P. Dever, Z. O. Adham, B. Thompson, et al., “Aryl Hydrocarbon Receptor Deletion in Cerebellar Granule Neuron Precursors Impairs Neurogenesis,” Developmental Neurobiology 76, no. 5 (2016): 533-550.

[144] S. E. Latchney, A. M. Hein, M. K. O'Banion, E. DiCicco-Bloom, and L. A. Opanashuk, “Deletion or Activation of the Aryl Hydrocarbon Receptor Alters Adult Hippocampal Neurogenesis and Contextual Fear Memory,” Journal of Neurochemistry 125, no. 3 (2013): 430-445.

[145] G. Shackleford, N. K. Sampathkumar, M. Hichor, et al., “Involvement of Aryl Hydrocarbon Receptor in Myelination and in human Nerve Sheath Tumorigenesis,” PNAS 115, no. 6 (2018): E1319-e1328.

[146] G. Bustani, H. Alghetaa, A. Mohammed, M. Nagarkatti, and P. Nagarkatti, “The Aryl Hydrocarbon Receptor: A New Frontier in Male Reproductive System,” Reproductive Biology and Endocrinology [Electronic Resource]: RB&E 23, no. 1 (2025): 70.

[147] C. Ko, Y. Fan, M. de Gannes, Q. Wang, Y. Xia, and A. Puga, “Repression of the Aryl Hydrocarbon Receptor Is Required to Maintain Mitotic Progression and Prevent Loss of Pluripotency of Embryonic Stem Cells,” Stem Cells 34, no. 12 (2016): 2825-2839.

[148] D. A. Hansen, P. Esakky, A. Drury, L. Lamb, and K. H. Moley, “The Aryl Hydrocarbon Receptor Is Important for Proper Seminiferous Tubule Architecture and Sperm Development in Mice,” Biology of Reproduction 90, no. 1 (2014): 8.

[149] K. M. Bircsak, L. T. Copes, S. King, A. M. Prantner, W. Hwang, and G. L. Gerton, “The Aryl Hydrocarbon Receptor Mediates Sex Ratio Distortion in the Embryos Sired by TCDD-exposed Male Mice,” Reproductive Toxicology 94 (2020): 75-83.

[150] J. Major, S. Crotta, K. Finsterbusch, et al., “Endothelial AHR Activity Prevents Lung Barrier Disruption in Viral Infection,” Nature 621, no. 7980 (2023): 813-820.

[151] L. Wang, Y. Tu, L. Chen, et al., “Black Rice Diet Alleviates Colorectal Cancer Development Through Modulating Tryptophan Metabolism and Activating AHR Pathway,” Imeta 3, no. 1 (2024): e165.

[152] N. V. Wieser, M. Ghiboub, C. Verseijden, et al., “Exploring the Immunomodulatory Potential of Human Milk: Aryl Hydrocarbon Receptor Activation and Its Impact on Neonatal Gut Health,” Nutrients 16, no. 10 (2024): 1531.

[153] C. Siegel and L. Sammaritano, “Systemic Lupus Erythematosus: A Review,” Jama 331, no. 17 (2024): 1480-1491.

[154] C. Law, V. S. Wacleche, Y. Cao, et al., “Interferon Subverts an AHR-JUN Axis to Promote CXCL13(+) T Cells in Lupus,” Nature 631, no. 8022 (2024): 857-866.

[155] R. Felten, D. Lipsker, J. Sibilia, F. Chasset, and L. Arnaud, “The History of Lupus throughout the Ages,” Journal of the American Academy of Dermatology 87, no. 6 (2022): 1361-1369.

[156] S. A. Jenks, K. S. Cashman, M. C. Woodruff, F. E. Lee, and I. Sanz, “Extrafollicular Responses in Humans and SLE,” Immunological Reviews 288, no. 1 (2019): 136-148.

[157] S. H. Smith, C. Jayawickreme, D. J. Rickard, et al., “Tapinarof Is a Natural AhR Agonist That Resolves Skin Inflammation in Mice and Humans,” Journal of Investigative Dermatology 137, no. 10 (2017): 2110-2119.

[158] L. Ting, S. Mingjun, C. Yuanyan, et al., “Association Between AhR in B Cells and Systemic Lupus Erythematosus With Renal Damage,” International Immunopharmacology 113, no. Pt A (2022): 109381.

[159] M. Kostopoulou, C. B. Mukhtyar, G. Bertsias, D. T. Boumpas, and A. Fanouriakis, “Management of Systemic Lupus erythematosus: A Systematic Literature Review Informing the 2023 Update of the EULAR Recommendations,” Annals of the Rheumatic Diseases 83, no. 11 (2024): 1489-1501.

[160] R. Shinde, K. Hezaveh, M. J. Halaby, et al., “Apoptotic Cell-induced AhR Activity Is Required for Immunological Tolerance and Suppression of Systemic Lupus Erythematosus in Mice and Humans,” Nature Immunology 19, no. 6 (2018): 571-582.

[161] D. Zhong, C. Wu, X. Zeng, and Q. Wang, “The Role of Gut Microbiota in the Pathogenesis of Rheumatic Diseases,” Clinical Rheumatology 37, no. 1 (2018): 25-34.

[162] A. Jarade, J. Di Santo, and N. Serafini, “Group 3 Innate Lymphoid Cells Mediate Host Defense Against Attaching and Effacing Pathogens,” Current Opinion in Microbiology 63 (2021): 83-91.

[163] N. Hanlon, N. Gillan, J. Neil, and K. Seidler, “The Role of the Aryl Hydrocarbon Receptor (AhR) in Modulating Intestinal ILC3s to Optimise Gut Pathogen Resistance in Lupus and Benefits of Nutritional AhR Ligands,” Clinical Nutrition 43, no. 6 (2024): 1199-1215.

[164] H. Ahmadi, M. Mahmoudi, F. Gharibdoost, et al., “Targeting of Circulating Th17 Cells by β-D-mannuronic Acid (M2000) as a Novel Medication in Patients With Rheumatoid Arthritis,” Inflammopharmacology 26, no. 1 (2018): 57-65.

[165] N. Nguyen, T. Nakahama, and T. Kishimoto, “Aryl Hydrocarbon Receptor and Experimental Autoimmune Arthritis,” Seminars in Immunopathology 35, no. 6 (2013): 637-644.

[166] X. Yang, H. Liu, T. Ye, et al., “AhR Activation Attenuates Calcium Oxalate Nephrocalcinosis by Diminishing M1 Macrophage Polarization and Promoting M2 Macrophage Polarization,” Theranostics 10, no. 26 (2020): 12011-12025.

[167] K. Psianou, I. Panagoulias, A. D. Papanastasiou, et al., “Clinical and Immunological Parameters of Sjögren's Syndrome,” Autoimmunity Reviews 17, no. 10 (2018): 1053-1064.

[168] J. Tian, K. Rui, Y. Hong, et al., “Increased GITRL Impairs the Function of Myeloid-Derived Suppressor Cells and Exacerbates Primary Sjögren Syndrome,” Journal of Immunology 202, no. 6 (2019): 1693-1703.

[169] S. Jangi, R. Gandhi, L. M. Cox, et al., “Alterations of the human Gut Microbiome in Multiple Sclerosis,” Nature Communications 7 (2016): 12015.

[170] S. Abbaszadeh, M. Tabary, A. Aryannejad, et al., “Air Pollution and Multiple Sclerosis: A Comprehensive Review,” Neurological Sciences 42, no. 10 (2021): 4063-4072.

[171] A. McDonald, A. Nicaise, E. R. Sears, A. Bell, E. Kummari, and B. L. F. Kaplan, “Potential for TCDD to Induce Regulatory Functions in B Cells as Part of the Mechanism for T Cell Suppression in EAE,” Toxicology and Applied Pharmacology 454 (2022): 116259.

[172] M. Rouse, N. P. Singh, P. S. Nagarkatti, and M. Nagarkatti, “Indoles Mitigate the Development of Experimental Autoimmune Encephalomyelitis by Induction of Reciprocal Differentiation of Regulatory T Cells and Th17 Cells,” British Journal of Pharmacology 169, no. 6 (2013): 1305-1321.

[173] C. Zhu, Q. Xie, and B. Zhao, “The Role of AhR in Autoimmune Regulation and Its Potential as a Therapeutic Target Against CD4 T Cell Mediated Inflammatory Disorder,” International Journal of Molecular Sciences 15, no. 6 (2014): 10116-10135.

[174] V. Rothhammer, I. D. Mascanfroni, L. Bunse, et al., “Type I Interferons and Microbial Metabolites of Tryptophan Modulate Astrocyte Activity and central Nervous System Inflammation via the Aryl Hydrocarbon Receptor,” Nature Medicine 22, no. 6 (2016): 586-597.

[175] T. Zelante, G. Paolicelli, F. Fallarino, et al., “A Microbially Produced AhR Ligand Promotes a Tph1-driven Tolerogenic Program in Multiple Sclerosis,” Scientific Reports 14, no. 1 (2024): 6651.

[176] G. Anderson, “Type I Diabetes Pathoetiology and Pathophysiology: Roles of the Gut Microbiome, Pancreatic Cellular Interactions, and the ‘Bystander’ Activation of Memory CD8(+) T Cells,” International Journal of Molecular Sciences 24, no. 4 (2023): 3300.

[177] C. Sorini, I. Cosorich, M. Lo Conte, et al., “Loss of Gut Barrier Integrity Triggers Activation of Islet-reactive T Cells and Autoimmune Diabetes,” PNAS 116, no. 30 (2019): 15140-15149.

[178] L. D. Teixeira, N. A. Harrison, D. R. da Silva, C. E. Mathews, C. F. Gonzalez, and G. L. Lorca, “Nanovesicles from Lactobacillus Johnsonii N6.2 Reduce Apoptosis in Human Beta Cells by Promoting AHR Translocation and IL10 Secretion,” Frontiers in Immunology 13 (2022): 899413.

[179] N. I. Kerkvliet, L. B. Steppan, W. Vorachek, et al., “Activation of Aryl Hydrocarbon Receptor by TCDD Prevents Diabetes in NOD Mice and Increases Foxp3+ T Cells in Pancreatic Lymph Nodes,” Immunotherapy 1, no. 4 (2009): 539-547.

[180] H. M. Kahalehili, N. K. Newman, J. M. Pennington, et al., “Dietary Indole-3-Carbinol Activates AhR in the Gut, Alters Th17-Microbe Interactions, and Exacerbates Insulitis in NOD Mice,” Frontiers in Immunology 11 (2020): 606441.

[181] T. Yue, F. Sun, C. Yang, et al., “The AHR Signaling Attenuates Autoimmune Responses during the Development of Type 1,” Diabetes Front Immunol 11 (2020): 1510.

[182] Y. Wang, H. Feng, X. Nie, et al., “Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy,” Frontiers in Pharmacology 13 (2022): 907108.

[183] H. Miao, Y. Zhang, X. Yu, L. Zou, and Y. Zhao, “Membranous Nephropathy: Systems Biology-based Novel Mechanism and Traditional Chinese Medicine Therapy,” Frontiers in Pharmacology 13 (2022): 969930.

[184] M. Gu, P. Ying, Z. Miao, et al., “Treatment of Modified Dahuang Fuzi Decoction on Cognitive Impairment Induced by Chronic Kidney Disease Through Regulating AhR/NF-κB/JNK Signal Pathway,” Evidence-Based Complementary and Alternative Medicine 2022 (2022): 8489699.

[185] X. Liu, R. Deng, Y. Chen, et al., “Jian-Pi-Yi-Shen Formula Improves Adenine-Induced Chronic Kidney Disease via Regulating Tryptophan Metabolism and Aryl Hydrocarbon Receptor Signaling,” Frontiers in Pharmacology 13 (2022): 922707.

[186] H. Miao, Y. Wang, X. Yu, et al., “Lactobacillus Species Ameliorate Membranous Nephropathy Through Inhibiting the Aryl Hydrocarbon Receptor Pathway via Tryptophan-produced Indole Metabolites,” British Journal of Pharmacology 181, no. 1 (2024): 162-179.

[187] D. Mandlik and S. Mandlik, “Atopic Dermatitis: New Insight Into the Etiology, Pathogenesis, Diagnosis and Novel Treatment Strategies,” Immunopharmacology and Immunotoxicology 43, no. 2 (2021): 105-125.

[188] H. O. Kim, J. H. Kim, B. Y. Chung, M. G. Choi, and C. W. Park, “Increased Expression of the Aryl Hydrocarbon Receptor in Patients With Chronic Inflammatory Skin Diseases,” Experimental Dermatology 23, no. 4 (2014): 278-281.

[189] M. Furue, “Regulation of Skin Barrier Function via Competition Between AHR Axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 Axis: Pathogenic and Therapeutic Implications in Atopic Dermatitis,” Journal of Clinical Medicine 9, no. 11 (2020): 3741.

[190] Z. Chen, M. Dragan, P. Sun, et al., “The AhR-Ovol1-Id1 Regulatory Axis in Keratinocytes Promotes Epidermal and Immune Homeostasis in Atopic Dermatitis-Like Skin Inflammation,” Cellular & Molecular Immunology 22, no. 3 (2025): 300-315.

[191] R. Bissonnette, E. Saint-Cyr Proulx, C. Jack, and C. Maari, “Tapinarof for Psoriasis and Atopic Dermatitis: 15 Years of Clinical Research,” Journal of the European Academy of Dermatology and Venereology 37, no. 6 (2023): 1168-1174.

[192] S. Müller, L. Maintz, and T. Bieber, “Treatment of Atopic Dermatitis: Recently Approved Drugs and Advanced Clinical Development Programs,” Allergy 79, no. 6 (2024): 1501-1515.

[193] J. I. Silverberg, L. F. Eichenfield, A. A. Hebert, et al., “Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials,” Journal of the American Academy of Dermatology 91, no. 3 (2024): 457-465.

[194] V. Yadav, F. Varum, R. Bravo, E. Furrer, D. Bojic, and A. W. Basit, “Inflammatory Bowel Disease: Exploring Gut Pathophysiology for Novel Therapeutic Targets,” Translational Research 176 (2016): 38-68.

[195] S. Lee, J. Kwon, and M. Cho, “Immunological Pathogenesis of Inflammatory Bowel Disease,” Intestinal Research 16, no. 1 (2018): 26-42.

[196] T. Feng, H. Qin, L. Wang, E. N. Benveniste, C. O. Elson, and Y. Cong, “Th17 cells Induce Colitis and Promote Th1 Cell Responses Through IL-17 Induction of Innate IL-12 and IL-23 Production,” Journal of Immunology 186, no. 11 (2011): 6313-6318.

[197] N. T. Van, K. Zhang, R. M. Wigmore, et al., “Dietary L-Tryptophan Consumption Determines the Number of Colonic Regulatory T Cells and Susceptibility to Colitis via GPR15,” Nature Communications 14, no. 1 (2023): 7363.

[198] J. D. Abron, N. P. Singh, M. K. Mishra, et al., “An Endogenous Aryl Hydrocarbon Receptor Ligand, ITE, Induces Regulatory T Cells and Ameliorates Experimental Colitis,” American journal of physiology Gastrointestinal and liver physiology 315, no. 2 (2018): G220-g230.

[199] T. Ji, C. Xu, L. Sun, et al., “Aryl Hydrocarbon Receptor Activation Down-Regulates IL-7 and Reduces Inflammation in a Mouse Model of DSS-Induced Colitis,” Digestive Diseases and Sciences 60, no. 7 (2015): 1958-1966.

[200] J. Benson and D. Shepherd, “Aryl Hydrocarbon Receptor Activation by TCDD Reduces Inflammation Associated With Crohn's Disease,” Toxicological Sciences 120, no. 1 (2011): 68-78.

[201] A. Kubota, M. Terasaki, R. Takai, M. Kobayashi, R. Muromoto, and H. Kojima, “5-Aminosalicylic Acid, a Weak Agonist for Aryl Hydrocarbon Receptor That Induces Splenic Regulatory T Cells,” Pharmacology 107, no. 1-2 (2022): 28-34.

[202] Q. Lv, K. Wang, S. Qiao, et al., “Norisoboldine, a Natural AhR Agonist, Promotes Treg Differentiation and Attenuates Colitis via Targeting Glycolysis and Subsequent NAD(+)/SIRT1/SUV39H1/H3K9me3 Signaling Pathway,” Cell Death & Disease 9, no. 3 (2018): 258.

[203] B. Shen, “Acute and Chronic Pouchitis-pathogenesis, Diagnosis and Treatment,” Nature Reviews Gastroenterology & hepatology 9, no. 6 (2012): 323-333.

[204] T. Zhang, Z. Yu, Y. Xu, et al., “Tryptophan Metabolites Improve Intestinal Mucosal Barrier via the Aryl Hydrocarbon Receptor-Interleukin-22 Pathway in Murine Dextran Sulfate Sodium-Induced Pouchitis,” Diseases of the Colon and Rectum 68, no. 1 (2025): 77-90.

[205] C. Wang, Z. Ye, A. Kijlstra, Y. Zhou, and P. Yang, “Activation of the Aryl Hydrocarbon Receptor Affects Activation and Function of human Monocyte-derived Dendritic Cells,” Clinical and Experimental Immunology 177, no. 2 (2014): 521-530.

[206] L. Zhou, D. Wu, Y. Zhou, et al., “Tumor Cell-released Kynurenine Biases MEP Differentiation Into Megakaryocytes in Individuals With Cancer by Activating AhR-RUNX1,” Nature Immunology 24, no. 12 (2023): 2042-2052.

[207] L. Wang, K. Liu, S. Wang, et al., “Aryl Hydrocarbon Receptor-kynurenine Axis Promotes Oncogenic Activity in BCP-ALL,” Cell Biology and Toxicology 39, no. 4 (2023): 1471-1487.

[208] P. Xue, J. Fu, and Y. Zhou, “The Aryl Hydrocarbon Receptor and Tumor Immunity,” Frontiers in Immunology 9 (2018): 286.

[209] L. Partecke, C. Günther, S. Hagemann, et al., “Induction of M2-macrophages by Tumour Cells and Tumour Growth Promotion by M2-macrophages: A Quid Pro Quo in Pancreatic Cancer,” Pancreatology 13, no. 5 (2013): 508-516.

[210] O. W. Yeung, C. Lo, C. Ling, et al., “Alternatively Activated (M2) Macrophages Promote Tumour Growth and Invasiveness in Hepatocellular Carcinoma,” Journal of Hepatology 62, no. 3 (2015): 607-616.

[211] Y. Zhang, W. Sime, M. Juhas, and A. Sjölander, “Crosstalk Between Colon Cancer Cells and Macrophages via Inflammatory Mediators and CD47 Promotes Tumour Cell Migration,” European Journal of Cancer 49, no. 15 (2013): 3320-3334.

[212] X. Jiang, J. Wang, L. Lin, et al., “Macrophages Promote Pre-metastatic Niche Formation of Breast Cancer Through Aryl Hydrocarbon Receptor Activity,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 352.

[213] C. A. Opitz, U. M. Litzenburger, F. Sahm, et al., “An Endogenous Tumour-promoting Ligand of the human Aryl Hydrocarbon Receptor,” Nature 478, no. 7368 (2011): 197-203.

[214] J. Ma, Y. Wu, L. Ma, et al., “A Blueprint for Tumor-infiltrating B Cells Across human Cancers,” Science 384, no. 6695 (2024): eadj4857.

[215] C. G. Atene, S. Fiorcari, N. Mesini, et al., “Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia via Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation,” Frontiers in Immunology 13 (2022): 832263.

[216] N. E. Olafsen, S. Das, C. Gorrini, and J. Matthews, “Long-term Exposure to BAY2416964 Reduces Proliferation, Migration and Recapitulates Transcriptional Changes Induced by AHR Loss in PyMT-induced Mammary Tumor Cells,” Frontiers in Oncology 14 (2024): 1466658.

[217] J. Wagner, C. Brunstein, A. Boitano, et al., “Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft,” Cell Stem Cell 18, no. 1 (2016): 144-155.

[218] M. McKean, D. H. Aggen, N. J. Lakhani, et al., “Phase 1a/b Open-label Study of IK-175, an Oral AHR Inhibitor, Alone and in Combination With nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma,” Journal of Clinical Oncology 40, no. 16_suppl (2022): TPS3169-TPS3169.

[219] F. Peyraud, J. Guegan, D. Bodet, S. Cousin, A. Bessede, and A. Italiano, “Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives,” Frontiers in Immunology 13 (2022): 807271.

[220] N. R. Coelho, A. B. Pimpão, M. J. Correia, et al., “Pharmacological Blockage of the AHR-CYP1A1 Axis: A Call for in Vivo Evidence,” Journal of Molecular Medicine (Berlin) 100, no. 2 (2022): 215-243.

[221] K. J. Smith, I. A. Murray, R. Tanos, et al., “Identification of a High-affinity Ligand That Exhibits Complete Aryl Hydrocarbon Receptor Antagonism,” Journal of Pharmacology and Experimental Therapeutics 338, no. 1 (2011): 318-327.

[222] Y. Wang, Y. Mou, S. Lu, Y. Xia, and B. Cheng, “Polymethoxylated Flavonoids in Citrus Fruits: Absorption, Metabolism, and Anticancer Mechanisms Against Breast Cancer,” PeerJ 12 (2024): e16711.

[223] E. Kimura and C. Tohyama, “Embryonic and Postnatal Expression of Aryl Hydrocarbon Receptor mRNA in Mouse Brain,” Frontiers in Neuroanatomy 11 (2017): 4.

[224] L. L. Collins, M. A. Williamson, B. D. Thompson, D. P. Dever, T. A. Gasiewicz, and L. A. Opanashuk, “2,3,7,8-Tetracholorodibenzo-p-dioxin Exposure Disrupts Granule Neuron Precursor Maturation in the Developing Mouse Cerebellum,” Toxicological Sciences 103, no. 1 (2008): 125-136.

[225] C. R. Filbrandt, Z. Wu, B. Zlokovic, L. Opanashuk, and T. A. Gasiewicz, “Presence and Functional Activity of the Aryl Hydrocarbon Receptor in Isolated Murine Cerebral Vascular Endothelial Cells and Astrocytes,” Neurotoxicology 25, no. 4 (2004): 605-616.

[226] Y. Li, G. Chen, J. Zhao, et al., “2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) Induces Microglial Nitric Oxide Production and Subsequent Rat Primary Cortical Neuron Apoptosis Through p38/JNK MAPK Pathway,” Toxicology 312 (2013): 132-141.

[227] R. Lowery, S. Latchney, R. Peer, et al., “Gestational and Lactational Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin Primes Cortical Microglia to Tissue Injury,” Brain, Behavior, and Immunity 101 (2022): 288-303.

[228] X. Qian, Q. Li, H. Zhu, et al., “Bifidobacteria With Indole-3-lactic Acid-producing Capacity Exhibit Psychobiotic Potential via Reducing Neuroinflammation,” Cell Reports Medicine 5, no. 11 (2024): 101798.

[229] H. Kim, E. Lee, M. Park, et al., “Microbiome-derived Indole-3-lactic Acid Reduces Amyloidopathy Through Aryl-hydrocarbon Receptor Activation,” Brain, Behavior, and Immunity 122 (2024): 568-582.

[230] Y. Lee, C. Lin, P. Hsu, et al., “Aryl Hydrocarbon Receptor Mediates both Proinflammatory and Anti-inflammatory Effects in Lipopolysaccharide-activated Microglia,” Glia 63, no. 7 (2015): 1138-1154.

[231] N. Ma, T. He, L. J. Johnston, and X. Ma, “Host-microbiome Interactions: The Aryl Hydrocarbon Receptor as a Critical Node in Tryptophan Metabolites to Brain Signaling,” Gut Microbes 11, no. 5 (2020): 1203-1219.

[232] T. Wang, B. Chen, M. Luo, et al., “Microbiota-indole 3-propionic Acid-brain Axis Mediates Abnormal Synaptic Pruning of Hippocampal Microglia and Susceptibility to ASD in IUGR Offspring,” Microbiome 11, no. 1 (2023): 245.

[233] Y. Wang, J. Sun, K. Zhu, et al., “Microglial Aryl Hydrocarbon Receptor Enhances Phagocytic Function via SYK and Promotes Remyelination in the cuprizone Mouse Model of Demyelination,” J Neuroinflammation 20, no. 1 (2023): 83.

[234] C. Qian, C. Yang, M. Lu, et al., “Activating AhR Alleviates Cognitive Deficits of Alzheimer's Disease Model Mice by Upregulating Endogenous Aβ Catabolic Enzyme Neprilysin,” Theranostics 11, no. 18 (2021): 8797-8812.

[235] M. Wormke, M. Stoner, B. Saville, et al., “The Aryl Hydrocarbon Receptor Mediates Degradation of Estrogen Receptor Alpha Through Activation of Proteasomes,” Molecular and Cellular Biology 23, no. 6 (2003): 1843-1855.

[236] V. De Castro, O. Abdellaoui, B. Dehecq, et al., “Characterization of the Aryl Hydrocarbon Receptor as a Potential Candidate to Improve Cancer T Cell Therapies,” Cancer Immunology, Immunotherapy 74, no. 7 (2025): 200.

[237] M. Omidi, A. Ghafarian-Bahraman, and A. Mohammadi-Bardbori, “GSH/GSSG Redox Couple Plays central Role in Aryl Hydrocarbon Receptor-dependent Modulation of Cytochrome P450 1A1,” Journal of Biochemical and Molecular Toxicology (2018): e22164.

[238] L. Yan, L. Gu, X. Lv, et al., “Butylphthalide Mitigates Traumatic Brain Injury by Activating Anti-ferroptotic AHR-CYP1B1 Pathway,” Journal of Ethnopharmacology 337, no. Pt 1 (2025): 118758.

[239] L. Cai, D. Yu, Y. Gao, C. Yang, H. Zhou, and Z. K. Chen, “Activation of Aryl Hydrocarbon Receptor Prolongs Survival of Fully Mismatched Cardiac Allografts,” Journal of Huazhong University of Science and Technology Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao Yixue Yingdewen Ban 33, no. 2 (2013): 199-204.

[240] T. Huang, J. Song, J. Gao, et al., “Adipocyte-derived Kynurenine Promotes Obesity and Insulin Resistance by Activating the AhR/STAT3/IL-6 Signaling,” Nature Communications 13, no. 1 (2022): 3489.

[241] J. P. Saiki, J. O. Andreasson, K. V. Grimes, et al., “Treatment-refractory Ulcerative Colitis Responsive to indigo naturalis,” BMJ Open Gastroenterol 8, no. 1 (2021): e000813.

[242] A. Igarashi, G. Tsuji, S. Fukasawa, R. Murata, and S. Yamane, “Tapinarof Cream for the Treatment of Atopic Dermatitis: Efficacy and Safety Results From Two Japanese Phase 3 Trials,” Journal of Dermatology 51, no. 11 (2024): 1404-1413.

[243] C. M. Polonio, K. A. McHale, D. H. Sherr, D. Rubenstein, and F. J. Quintana, “The Aryl Hydrocarbon Receptor: A Rehabilitated Target for Therapeutic Immune Modulation,” Nature Reviews Drug Discovery 24, no. 8 (2025): 610-630.

[244] W. M. de Vos, H. Tilg, M. Van Hul, and P. D. Cani, “Gut Microbiome and Health: Mechanistic Insights,” Gut 71, no. 5 (2022): 1020-1032.

[245] J. Stange and M. Veldhoen, “The Aryl Hydrocarbon Receptor in Innate T Cell Immunity,” Seminars in immunopathology 35, no. 6 (2013): 645-655.

[246] T. Zelante, R. Iannitti, C. Cunha, et al., “Tryptophan Catabolites From Microbiota Engage Aryl Hydrocarbon Receptor and Balance Mucosal Reactivity via Interleukin-22,” Immunity 39, no. 2 (2013): 372-385.

[247] R. Aoki, A. Aoki-Yoshida, C. Suzuki, and Y. Takayama, “Indole-3-Pyruvic Acid, an Aryl Hydrocarbon Receptor Activator, Suppresses Experimental Colitis in Mice,” Journal of Immunology 201, no. 12 (2018): 3683-3693.

[248] A. Salminen, “Activation of Aryl Hydrocarbon Receptor (AhR) in Alzheimer's Disease: Role of Tryptophan Metabolites Generated by Gut Host-microbiota,” Journal of Molecular Medicine (Berlin) 101, no. 3 (2023): 201-222.

[249] L. Wu, Y. Han, Z. Zheng, et al., “Altered Gut Microbial Metabolites in Amnestic Mild Cognitive Impairment and Alzheimer's Disease: Signals in Host-Microbe Interplay,” Nutrients 13, no. 1 (2021).

[250] S. Xiang, J. Ji, S. Li, et al., “Efficacy and Safety of Probiotics for the Treatment of Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease: A Systematic Review and Meta-Analysis,” Frontiers in Aging Neuroscience 14 (2022): 730036.

[251] D. Dolciami, M. Ballarotto, M. Gargaro, L. C. López-Cara, F. Fallarino, and A. Macchiarulo, “Targeting Aryl Hydrocarbon Receptor for next-generation Immunotherapies: Selective Modulators (SAhRMs) versus Rapidly Metabolized Ligands (RMAhRLs),” European Journal of Medicinal Chemistry 185 (2020): 111842.

[252] J. Gruszczyk, L. Grandvuillemin, J. Lai-Kee-Him, et al., “Cryo-EM Structure of the Agonist-bound Hsp90-XAP2-AHR Cytosolic Complex,” Nature Communications 13, no. 1 (2022): 7010.

[253] T. Haarmann-Stemmann, D. Reichert, X. Coumoul, et al., “The Janus-facedness of the Aryl Hydrocarbon Receptor Pathway Report of the 6th International AHR Meeting: Research, Prevention, Therapy,” Biochemical Pharmacology 234 (2025): 116808.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.